Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
For research use only. We do not sell to patients.
Name | Palbociclib |
---|---|
Iupac Chemical Name | 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one |
Synonyms | Palbociclib;PD-0332991 |
Molecular Formula | C24H29N7O2 |
Molecular Weight | 447.53 |
Smile | C(C)(=O)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)N(C1=O)C1CCCC1)C |
InChiKey | AHJRHEGDXFFMBM-UHFFFAOYSA-N |
InChi | InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29) |
CAS Number | 571190-30-2 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | yellow solid |
---|---|
Purity | ≧98.0% |
Storage | 3 years -20ºCpowder |
Solubility | 5mg/ml in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |